Results

1–10 of 29 results for intravitreal aflibercept

Naive SubRetinal Hemorrhage in Neovascular AMD—Pneumatic Displacement, Subretinal Air, and tPA: Subretinal vs Intravitreal Aflibercept: The NATIVE Study
Matias Iglicki, MD
Annual Meeting Talks
2023
Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Week 48 Efficacy Outcomes by Baseline Demographics in the Phase 2/3 PHOTON Trial
Andres Emanuelli, MD
Annual Meeting Talks
2023
Subgroup Analyses From the Phase 3 PULSAR Trial of Aflibercept 8 mg in Patients With Treatment-Naïve Neovascular Age-Related Macular Degeneration
Keyvan Koushan, MD, FRCSC
Annual Meeting Talks
2023
Intravitreal Aflibercept 8 mg in Patients With Polypoidal Choroidal Vasculopathy Phase 3 PULSAR Trial Subgroup Analysis
David T.W. Wong, MD, FRCS(C), FASRS
Annual Meeting Talks
2023
Baseline Characteristics of Patients Maintaining q12 and q16 Dosing With Aflibercept 8 mg vs Patients With Shortened Treatment Intervals Phase 3 PULSAR Post Hoc Analysis
David R. Chow, MD, FRCS(C)
Annual Meeting Talks
2023
Intravitreal Aflibercept 8 mg Injection in Patients With Neovascular Age-Related Macular Degeneration: 48-week Results From the Phase 3 PULSAR Trial
Jignesh I Patel, MD FRCOphth
Annual Meeting Talks
2023
Effects of Time Since Diagnosis to Intravitreal Aflibercept Injection and Baseline BCVA on Outcomes in CRVO: Post Hoc Analysis of the COPERNICUS and GALILEO Trials
Dilsher S. Dhoot, MD
Annual Meeting Talks
2022
Prospective Randomized Trial of Treat-and-Extend Intravitreal Aflibercept for Radiation Retinopathy: One-Year Outcomes
Amy C. Schefler, MD FACS FASRS
Annual Meeting Talks
2022
Baseline Factors Influencing Diabetic Macular Edema (DME) Resolution After Intravitreal Aflibercept Injection (IAI) or Laser Treatment in VISTA/VIVID
W. Lloyd Clark, MD, FASRS
Annual Meeting Talks
2021
Evaluation of 8 mg Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration: Results from the Phase 2 CANDELA Study
W. Lloyd Clark, MD, FASRS
Updates from the Field
2022